GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ginkgo Bioworks Holdings Inc (NYSE:DNA) » Definitions » Financial Strength

DNA (Ginkgo Bioworks Holdings) Financial Strength : 4 (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Ginkgo Bioworks Holdings Financial Strength?

Ginkgo Bioworks Holdings has the Financial Strength Rank of 4.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.

A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Ginkgo Bioworks Holdings did not have earnings to cover the interest expense. Ginkgo Bioworks Holdings's debt to revenue ratio for the quarter that ended in Dec. 2024 was 2.67. As of today, Ginkgo Bioworks Holdings's Altman Z-Score is -6.26.


Competitive Comparison of Ginkgo Bioworks Holdings's Financial Strength

For the Biotechnology subindustry, Ginkgo Bioworks Holdings's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ginkgo Bioworks Holdings's Financial Strength Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ginkgo Bioworks Holdings's Financial Strength distribution charts can be found below:

* The bar in red indicates where Ginkgo Bioworks Holdings's Financial Strength falls into.


;
;

Ginkgo Bioworks Holdings Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Ginkgo Bioworks Holdings's Interest Expense for the months ended in Dec. 2024 was $-0.0 Mil. Its Operating Income for the months ended in Dec. 2024 was $-99.4 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $438.8 Mil.

Ginkgo Bioworks Holdings's Interest Coverage for the quarter that ended in Dec. 2024 is

Ginkgo Bioworks Holdings did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Ginkgo Bioworks Holdings's Debt to Revenue Ratio for the quarter that ended in Dec. 2024 is

Debt to Revenue Ratio=Total Debt (Q: Dec. 2024 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(28.965 + 438.766) / 175.388
=2.67

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Ginkgo Bioworks Holdings has a Z-score of -6.26, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of -6.26 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ginkgo Bioworks Holdings  (NYSE:DNA) Financial Strength Explanation

The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Ginkgo Bioworks Holdings has the Financial Strength Rank of 4.


Ginkgo Bioworks Holdings Financial Strength Related Terms

Thank you for viewing the detailed overview of Ginkgo Bioworks Holdings's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Ginkgo Bioworks Holdings Business Description

Traded in Other Exchanges
Address
27 Drydock Avenue, 8th Floor, Boston, MA, USA, 02210
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
Executives
Steven P. Coen officer: Chief Accounting Officer C/O GINKGO BIOWORKS HOLDINGS, INC., 27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON MA 02210
Mark E. Dmytruk officer: Chief Financial Officer C/O SOARING EAGLE ACQUISITION CORP., 955 FIFTH AVENUE, NEW YORK NY 10075
Marijn E Dekkers director GENERAL ELECTRIC COMPANY, 41 FARNSWORTH STREET, BOSTON MA 02210
Shyam Sankar director C/O PALANTIR TECHNOLOGIES INC., 1200 17TH STREET, FLOOR 15, DENVER CO 80202
Harry Sloan director, officer: CEO, Chairman 1450 2ND STREET, SUITE 247, SANTA MONICA CA 90401
Jason R Kelly director, officer: CEO & Founder 667 MADISON AVENUE, C/O CORVEX MANAGEMENT LP, NEW YORK NY 10065
Barry Canton 10 percent owner C/O GINKGO BIOWORKS, INC., 27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON MA 02210
Reshma P. Shetty director, 10 percent owner, officer: President, COO & Founder C/O SOARING EAGLE ACQUISITION CORP., 955 FIFTH AVENUE, NEW YORK NY 10075
Christian O Henry director 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Marie E. Fallon officer: Chief Accounting Officer C/O GINKGO BIOWORKS, INC., 27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON MA 02210
Kathy Hopinkah Hannan director ANNALY CAPITAL MANAGEMENT, INC., 1211 AVE. OF THE AMERICAS, NEW YORK NY 10036
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Illiquid Investments Sub-master Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Ole Andreas Halvorsen 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901